Modified hexa-acylated neisserial LPS
The present invention relates to neisserial LPS having a hexa-acylated lipid A moiety, wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it comprises a palmitoleoyl instead of a lauroyl secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention further relates to mixtures of the hexa-acylated LPS with the corresponding penta-acylated LPS, lacking a secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention also relates to neisserial bacteria that have been genetically modified to reduce expression of the endogenous lpxL1 gene and to introduce expression of a heterologous thermosensitive lpxP gene for producing the hexa- and penta-acylated LPS. By selecting the time and/or temperature at which the bacterium is grown, it is feasible to increase or decrease the amount of hexa-acylated lipid A structure relative to the corresponding penta-acylated structure and thereby modulate the TLR4 agonist activity of the neisserial LPS of the invention, to the exact level of activity required for a particular immunotherapeutic approach.
1. A composition comprising a mixture of
i) a neisserial LPS having a hexa-acylated lipid A moiety, wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it has a palmitoleoyl (instead of a lauroyl) as secondary acyl chain bound to the primary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety; and
ii) a neisserial LPS with a penta-acylated lipid A moiety wherein the penta-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it lacks the secondary acyl chain bound to the primary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety.
2. The composition of claim 1 , wherein the hexa-acylated neisserial LPS, except for the hexa-acylated lipid A moiety, has the structure of an LPS of Neisseria meningitidis, Neisseria gonorrhoeae or Neisseria lactamica.
3. The composition of claim 1 , wherein the hexa-acylated neisserial LPS, except for the hexa-acylated lipid A moiety, hard the structure of an LPS of a genetically modified Neisseria meningitidis, Neisseria gonorrhoeae or Neisseria lactamica that is at least one of lgtB − and galE − .
4. The composition of claim 1 , wherein the hexa-acylated lipid A moiety has the structure of formula (I):
wherein R 1 and R 2 , independently, are either —P(O)(OH) 2 , —[P(O)(OH)—O] 2 —H, —[P(O)(OH)—O] 2 —CH 2 CH 2 NH 2 , —[P(O)(OH)—O] 3 —CH 2 CH 2 NH 2 , —[P(O)(OH)—O] 3 —H or —P(O)(OH)—O—CH 2 CH 2 NH 2 .
5. The composition of claim 1 , wherein the penta-acylated neisserial LPS, except for the penta-acylated lipid A moiety, has the structure of an LPS of Neisseria meningitidis, Neisseria gonorrhoeae or Neisseria lactamica.
6. The composition of claim 1 , wherein the penta-acylated neisserial LPS, except for the penta-acylated lipid A moiety, has the structure of an LPS of a genetically modified Neisseria meningitidis, Neisseria gonorrhoeae or Neisseria lactamica that is at least one of lgtB − and galE − .
7. The composition of claim 1 , wherein the penta-acylated lipid A moiety has the structure of formula (II):
wherein R 1 and R 2 , independently, are either —P(O)(OH) 2 , —[P(O)(OH)—O] 2 —H, —[P(O)(OH)—O] 2 —CH 2 CH 2 NH 2 , —[P(O)(OH)—O] 3 —CH 2 CH 2 NH 2 , —[P(O)(OH)—O] 3 —H or —P(O)(OH)—O—CH 2 CH 2 NH 2 .
8. The composition of claim 1 , wherein the composition comprises the hexa-acylated neisserial LPS and the penta-acylated neisserial LPS in a molar ratio in the range of 1:400 to 1:1.25.
9. The composition of claim 1 , wherein the composition is an acellular vaccine, and wherein the composition optionally further comprises at least one non-neisserial antigen.
10. The composition of claim 1 , wherein the composition comprises an outer membrane vesicle (OMV) comprising the mixture of the hexa-acylated neisserial LPS and the penta-acylated neisserial LPS.
11. The composition of claim 10 , wherein the composition is an acellular vaccine and wherein the composition optionally further comprises at least one non-neisserial antigen.
12. The composition of claim 1 , wherein the composition comprises a genetically modified bacterium comprising the mixture of the hexa-acylated neisserial LPS and the penta-acylated neisserial LPS, wherein the genetically modified bacterium is a bacterium of the genus Neisseria , and wherein the bacterium comprises:
a) a genetic modification that eliminates the activity of a lipid A biosynthesis lauroyl acyltransferase encoded by an endogenous lpxL1 gene; and,
b) a genetic modification that confers to the bacterium lipid A biosynthesis palmitoleoyltransferase activity, wherein the genetic modification introduces the expression of an LpxP lipid A palmitoleyltransferase that has at least 95% amino acid sequence identity with SEQ ID NO: 4.
13. The composition of claim 12 , wherein the composition is a whole cell vaccine and wherein the composition optionally further comprises at least one non-neisserial antigen.
14. A process for producing the composition of claim 1 , wherein the process comprises the steps of:
a) cultivating a genetically modified bacterium of the genus Neisseria at a temperature in the range of 20-42° C., wherein the bacterium comprises:
i) a genetic modification that eliminates the activity of a lipid A biosynthesis lauroyl acyltransferase encoded by an endogenous lpxL1 gene; and,
ii) a genetic modification that confers to the bacterium lipid A biosynthesis palmitoleoyltransferase activity, wherein the genetic modification introduces the expression of an LpxP lipid A palmitoleoytransferase that has at least 95% amino acid sequence identity with SEQ ID No: 4; and,
b) optionally, at least one of extraction and purification of the mixture of LPSs.
15. The process of claim 14 , wherein the bacterium is a genetically modified Neisseria meningitidis, Neisseria gonorrhoeae or Neisseria lactamica.
16. The process of claim 14 , wherein:
the endogenous lxL1 gene is a gene encoding an LpxL1 protein having an amino acid sequence with at least 90% sequence identity with at least one of SEQ ID NO's: 1-3.
17. A process for producing the composition of claim 10 , wherein the process comprises the steps of:
a) cultivating a genetically modified bacterium of the genus Neisseria at a temperature in the range of 20-42° C., wherein the bacterium comprises:
i) a genetic modification that eliminates the activity of a lipid A biosynthesis lauroyl acyltransferase encoded by an endogenous lpxL1 gene; and,
ii) a genetic modification that confers to the bacterium lipid A biosynthesis palmitoleoyltransferase activity, wherein the genetic modification introduces the expression of an LpxP lipid A palmitoleoyltransferase that has at least 95% amino acid sequence identity with SEQ ID NO: 4; and,
b) optionally, extracting the OMV; and,
c) recovering the OMV, wherein the recovery at least comprises removal of the bacteria from the OMV.
18. The process of claim 17 , wherein the process is a detergent-free process.
19. The process of claim 14 , wherein in step a) the bacterium is cultured at a temperature lower than 37° C.
20. The process of claim 17 , wherein in step a) the bacterium is cultured at a temperature lower than 37° C.